Form 4: PROVECTUS CEO Acquires Convertible Note in 2025 Financing

PROVECTUS BIOPHARMACEUTICALS CEO Edward Pershing acquired an 8% unsecured convertible promissory note as part of the company's 2025 financing.

Summary

• Edward Pershing, CEO and Director of PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT), acquired an 8% unsecured convertible promissory note with a principal amount of $30,000.
• The note was issued on August 26, 2025, as part of the Issuer's 2025 Financing.
• The note is convertible into shares of Series D-1 Convertible Preferred Stock at a price of $2.862 per share.
• Automatic conversion of the note into Series D-1 Preferred Stock will occur on August 26, 2026, if not converted earlier.
• Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock.
• Series D-1 Preferred Stock will automatically convert into Common Stock on June 26, 2026, unless converted earlier.
• Edward Pershing also reported a disposition of 10,483 shares of Series D-1 Convertible Preferred Stock at a price of $0, with $1,300,000 reported as beneficially owned following this transaction.

Sentiment

Score: 6

Explanation: The acquisition of a convertible note by the CEO is a positive signal of insider confidence and participation in the company's financing. However, the reported disposition of preferred stock with ambiguous details introduces some uncertainty.

Positives

• CEO Edward Pershing's acquisition of a convertible note indicates insider confidence and direct investment in the company's future through its 2025 financing.

Negatives

• The reported disposition of 10,483 shares of Series D-1 Convertible Preferred Stock at a $0 price, with $1,300,000 reported as beneficially owned following the transaction, presents an unclear picture regarding the nature and implications of this specific preferred stock movement.

Risks

• Future conversion of the convertible note and Series D-1 Preferred Stock into common stock could lead to dilution for existing common shareholders.
• The value of the convertible note and preferred stock is subject to the company's performance and stock price fluctuations.

Future Outlook

The convertible note and Series D-1 Preferred Stock are structured with future automatic conversion dates, indicating a planned transition to common stock ownership, subject to earlier voluntary conversion.

Industry Context

Insider transactions, particularly acquisitions of convertible debt, are common in the biotechnology sector for early-stage or development-stage companies seeking to raise capital and align management interests with long-term growth.

Related Party Transactions

• Edward Pershing, as CEO and Director, is a related party to PROVECTUS BIOPHARMACEUTICALS, INC. His acquisition of the convertible note constitutes a related party transaction.

Stakeholder Impact

• Shareholders may experience potential dilution upon the conversion of the convertible note and Series D-1 Preferred Stock into common stock.
• The financing, supported by insider investment, could provide capital for company operations and strategic initiatives.

Next Steps

• Voluntary or automatic conversion of the 8% unsecured convertible promissory note into Series D-1 Convertible Preferred Stock.
• Voluntary or automatic conversion of Series D-1 Convertible Preferred Stock into Common Stock.

Key Dates

Keywords

PROVECTUS BIOPHARMACEUTICALS, PVCT, Edward Pershing, CEO, Director, Convertible Note, Series D-1 Preferred Stock, Insider Transaction, 2025 Financing, Equity Financing, Biotechnology